190 related articles for article (PubMed ID: 22272114)
1. Structural requirements of N-substituted spiropiperidine analogues as agonists of nociceptin/orphanin FQ receptor.
Bao P; Zhang X; Ren H; Li Y; Mu Z; Zhang S; Li G; Yang L
Int J Mol Sci; 2011; 12(12):8961-81. PubMed ID: 22272114
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR, homology modeling, and molecular docking studies on spiropiperidines analogues as agonists of nociceptin/orphanin FQ receptor.
Liu M; He L; Hu X; Liu P; Luo HB
Bioorg Med Chem Lett; 2010 Dec; 20(23):7004-10. PubMed ID: 20961754
[TBL] [Abstract][Full Text] [Related]
3. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
Meyer ME; Doshi A; Yasuda D; Zaveri NT
AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
[TBL] [Abstract][Full Text] [Related]
5. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
[TBL] [Abstract][Full Text] [Related]
6. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
[TBL] [Abstract][Full Text] [Related]
7. Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.
Daga PR; Zaveri NT
Proteins; 2012 Aug; 80(8):1948-61. PubMed ID: 22489047
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2.
Caldwell JP; Matasi JJ; Fernandez X; McLeod RL; Zhang H; Fawzi A; Tulshian DB
Bioorg Med Chem Lett; 2009 Feb; 19(4):1164-7. PubMed ID: 19147350
[TBL] [Abstract][Full Text] [Related]
10.
Shirvani P; Fassihi A
J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands.
Caldwell JP; Matasi JJ; Zhang H; Fawzi A; Tulshian DB
Bioorg Med Chem Lett; 2007 Apr; 17(8):2281-4. PubMed ID: 17289383
[TBL] [Abstract][Full Text] [Related]
12. A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety.
Ross TM; Battista K; Bignan GC; Brenneman DE; Connolly PJ; Liu J; Middleton SA; Orsini M; Reitz AB; Rosenthal DI; Scott MK; Vaidya AH
Bioorg Med Chem Lett; 2015 Feb; 25(3):602-6. PubMed ID: 25556095
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
Trapella C; Fischetti C; Pela' M; Lazzari I; Guerrini R; Calo' G; Rizzi A; Camarda V; Lambert DG; McDonald J; Regoli D; Salvadori S
Bioorg Med Chem; 2009 Jul; 17(14):5080-95. PubMed ID: 19527931
[TBL] [Abstract][Full Text] [Related]
14. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
15. Discovery and structure-activity relationships (SAR) of a novel class of 2-substituted N-piperidinyl indole-based nociceptin opioid receptor ligands.
Meyer ME; Doshi A; Polgar WE; Zaveri NT
Bioorg Med Chem; 2023 Sep; 92():117421. PubMed ID: 37573822
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Structure-Activity Relationships of Triazaspirodecanone Derivatives as Nociceptin/Orphanin FQ Receptor Ligands.
Corrado S; Battisti UM; Sorbi C; Tait A; Malfacini D; Camarda V; Calò G; Brasili L
Chem Biol Drug Des; 2015 Oct; 86(4):447-58. PubMed ID: 25546401
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
Daga PR; Polgar WE; Zaveri NT
J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
[TBL] [Abstract][Full Text] [Related]
19. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri NT
Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
[TBL] [Abstract][Full Text] [Related]
20. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
